Literature DB >> 17549359

Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.

Sung-Shin Park1, Sung-Won Kim.   

Abstract

Akt/PKB is a serine/threonine kinase that plays a crucial role in cell survival and apoptosis. Aberrant activation of pAkt is associated with various malignant human cancers, including breast carcinoma. In vitro studies show that pAkt activation is mediated by estrogen and acts as a downstream effector of HER2 with implications in breast cancer progression and drug resistance. We investigated the incidence of Akt activation in invasive ductal carcinoma and its correlation with other clinicopathological variables. Using tissue microarray technology, immunohistochemical expression of phosphorylated Akt (pAkt) at Ser-473 was evaluated in 127 cases of invasive ductal carcinomas, together with hormone receptors, HER2, p53, Ki-67 and other clinicopathological variables. Both nuclear and cytoplasmic expression was noted for pAkt, with 46 cases (36.2%) showing high cytoplasmic pAkt expression and 37 cases (29.1%) showing high nuclear pAkt expression. There was a significant association between both high cytoplasmic and nuclear pAkt expression with HER2 overexpression (both p<0.0001). There was also a positive correlation between high nuclear pAkt expression with both estrogen receptor and progesterone receptor status (p=0.042 and p=0.015, respectively). High cytoplasmic pAkt expression was associated with high Ki-67 expression (p=0.052), however, there was no association between pAkt and p53 expression. In the present study, activation of the Akt pathway shows strong association with HER2 overexpression, which is consistent with many in vitro studies. Our study also showed a positive correlation between pAkt and hormone receptors, which suggested the possible mechanism of endocrine resistance in ER-positive breast cancer. These results also suggest the prognostic value of pAkt and its importance in the prediction of therapeutic response in invasive ductal carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549359

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  Calmodulin binds HER2 and modulates HER2 signaling.

Authors:  Colin D White; Zhigang Li; David B Sacks
Journal:  Biochim Biophys Acta       Date:  2010-12-24

2.  Axl gene knockdown inhibits the metastasis properties of hepatocellular carcinoma via PI3K/Akt-PAK1 signal pathway.

Authors:  Jingchao Xu; Li Jia; Hongye Ma; Yanping Li; Zhenhai Ma; Yongfu Zhao
Journal:  Tumour Biol       Date:  2013-12-18

3.  Suppression of breast cancer proliferation and induction of apoptosis via AKT and ERK1/2 signal transduction pathways by synthetic polypeptide derived from viral macrophage inflammatory protein II.

Authors:  Qingling Yang; Changjie Chen; Zhifeng Yang; Yangjun Gao; Jie Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

4.  Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.

Authors:  Maëva Lion; Alexandre Harlé; Julia Salleron; Carole Ramacci; Mario Campone; Jean-Louis Merlin
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

5.  A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.

Authors:  Triantafyllia Koletsa; Ioannis Kostopoulos; Elpida Charalambous; Barbara Christoforidou; Eleni Nenopoulou; Vassiliki Kotoula
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

6.  Role of estrogen receptor signaling in breast cancer metastasis.

Authors:  Sudipa Saha Roy; Ratna K Vadlamudi
Journal:  Int J Breast Cancer       Date:  2011-12-19

7.  A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.

Authors:  Farah B Rahmatpanah; Zhenyu Jia; Xin Chen; Jessica E Char; Bozhao Men; Anna-Clara Franke; Frank E Jones; Michael McClelland; Dan Mercola
Journal:  Oncotarget       Date:  2015-01-20

8.  Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy.

Authors:  V Lapin; E A Shirdel; X Wei; J M Mason; I Jurisica; T W Mak
Journal:  Oncogenesis       Date:  2014-12-15       Impact factor: 7.485

9.  Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Authors:  Peter Grell; Pavel Fabian; Marta Khoylou; Lenka Radova; Ondrej Slaby; Roman Hrstka; Rostislav Vyzula; Marian Hajduch; Marek Svoboda
Journal:  Int J Oncol       Date:  2012-07-27       Impact factor: 5.650

10.  Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.

Authors:  Masao Fujiwara; Kunihiko Izuishi; Takanori Sano; Mohammad Akram Hossain; Shoji Kimura; Tsutomu Masaki; Yasuyuki Suzuki
Journal:  J Exp Clin Cancer Res       Date:  2008-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.